Ann Surg Treat Res.  2015 Jan;88(1):35-40. 10.4174/astr.2015.88.1.35.

Long-term outcomes of infrainguinal bypass surgery for patients with diabetes mellitus and tissue loss

• Jung H
• Cho J
• Kim HK
• Kim J
• Huh S

• KMID: 2167057
• DOI: http://doi.org/10.4174/astr.2015.88.1.35

Abstract

PURPOSE
To determine the long-term outcomes of patients with diabetes mellitus (DM) and tissue loss who have undergone infrainguinal bypass surgery (IBS).
METHODS
We retrospectively reviewed the medical records of 91 patients with DM and tissue loss who underwent IBS between July 2003 and December 2013. We determined the rates of overall survival (OS), amputation-free survival (AFS), limb salvage (LS), and graft patency (GP). In addition, we evaluated data to identify risk factors that affected long-term outcomes.
RESULTS
The mean age of patients was 66 +/- 8 years, and 78 patients (85.7%) were men. The locations of tissue loss were toe on 76 limbs (71.6%), heel on 6 limbs (5.7%) and others on 24 limbs (22.6%). Single lesions were found in 81 limbs (76.4%). According to categorization by distal anastomosis artery, there were 57 popliteal (53.8%) and 49 infrapopliteal bypasses (46.2%). Among infrapopliteal bypasses, 5 cases (10.2%) were sequential bypasses. The OS at 1, 3, and 5 years was 90.5%, 70.9%, and 44.2%, respectively. At 1, 3, and 5 years, the LS was 92.1%, 88.9%, 88.9%, respectively; and AFS was 84.4%, 67.6%, 45.7%, respectively. At 1, 3, and 5 years, the GP was 84.8%, 74.5%, and 69.8%, respectively. Renal failure was a negative predictor for OS, and female gender was a negative predictor for GP.
CONCLUSION
IBS for patients with DM and tissue loss led to acceptable OS, AFS, LS, and GP. Active revascularization for patients with DM and tissue loss can reduce the risk of major amputation.

Keyword

Infrainguinal bypass; Diabetes mellitus; Tissue loss

MeSH Terms

Amputation
Arteries
Diabetes Mellitus*
Extremities
Female
Heel
Humans
Limb Salvage
Male
Medical Records
Renal Insufficiency
Retrospective Studies
Risk Factors
Toes
Transplants

Figure

• 

  Fig. 1 (A) Limb salvage rate of groups classified by distal anastomotic artery was not significantly different (P = 0.059). a, above the knee popliteal bypass; b, below the knee popliteal bypass; c, crural bypass; d, pedal bypass. (B) Graft patency of groups classified by distal anastomotic artery was not significantly different (P = 0.637) a, above the knee popliteal bypass; b, below the knee popliteal bypass; c, crural bypass; d, pedal bypass.

• 

  Fig. 2 (A) Survival rate of patients with renal insufficiency (RI) were significant lower than without RI (P = 0.011). (B) Female had lower graft patency than male (P = 0.022).

Reference

1. Faries PL, Teodorescu VJ, Morrissey NJ, Hollier LH, Marin ML. The role of surgical revascularization in the management of diabetic foot wounds. Am J Surg. 2004; 187(5A):34S–37S.

2. Global Lower Extremity Amputation Study Group. The Global Lower Extremity Amputation Study Group. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. Br J Surg. 2000; 87:328–337.

3. Carmona GA, Hoffmeyer P, Herrmann FR, Vaucher J, Tschopp O, Lacraz A, et al. Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab. 2005; 31:449–454.

4. Conte MS. Diabetic revascularization: endovascular versus open bypass: do we have the answer? Semin Vasc Surg. 2012; 25:108–114.

5. Cooper JC, Welsh CL. The role of percutaneous transluminal angioplasty in the treatment of critical ischaemia. Eur J Vasc Surg. 1991; 5:261–264.

6. Wahlgren CM, Kalin B, Lund K, Swedenborg J, Takolander R. Long-term outcome of infrainguinal percutaneous transluminal angioplasty. J Endovasc Ther. 2004; 11:287–293.

7. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997; 26:517–538.

8. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012; 28:Suppl 1. 179–217.

9. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003; 26:491–494.

10. Owens CD, Ho KJ, Kim S, Schanzer A, Lin J, Matros E, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg. 2007; 45:944–952.

11. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008; 47:975–981.

12. Albers M, Romiti M, Brochado-Neto FC, De Luccia N, Pereira CA. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg. 2006; 43:498–503.

13. Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, et al. Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013; 57:1455–1463.

14. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005; 41:423–435.

15. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010; 51:5 Suppl. 5S–17S.

16. Apelqvist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med. 1993; 233:485–491.

17. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. The EURODIALE Study. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. Diabetologia. 2008; 51:747–755.

18. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366:1719–1724.

19. Kota SK, Kota SK, Meher LK, Sahoo S, Mohapatra S, Modi KD. Surgical revascularization techniques for diabetic foot. J Cardiovasc Dis Res. 2013; 4:79–83.

20. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999; 22:157–162.

21. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002; 66:1655–1662.

22. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest. 1997; 99:1016–1027.

23. Vranes D, Cooper ME, Dilley RJ. Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res. 1999; 57:8–18.

24. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. N Engl J Med. 1984; 311:1615–1619.

25. Sandeman DD, Pym CA, Green EM, Seamark C, Shore AC, Tooke JE. Microvascular vasodilatation in feet of newly diagnosed non-insulin dependent diabetic patients. BMJ. 1991; 302:1122–1123.

26. Arora S, Pomposelli F, LoGerfo FW, Veves A. Cutaneous microcirculation in the neuropathic diabetic foot improves significantly but not completely after successful lower extremity revascularization. J Vasc Surg. 2002; 35:501–505.

27. Nguyen BN, Neville RF, Abugideiri M, Amdur R, Sidawy AN. The effect of graft configuration on 30-day failure of infrapopliteal bypasses. J Vasc Surg. 2014; 59:1003–1008.